Junshi hopes new scientist CEO can cure its woes
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…
FAST NEWS: Junshi Bio’s Loss Balloons on High R&D Spending
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced on Monday it expects to report its revenue dropped 64.1% to 1.45 billion yuan ($2.14 billion) last year,…
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Junshi Biosciences is facing business headwinds. Its key cancer drug has not sold as well as competing products and the company has yet to file a marketing application for its…
Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
FAST NEWS: Junshi Biosciences Revenue Doubles, Loss Narrows in 2021
The latest: Shanghai Junshi Biosciences Co. Ltd. (1877.HK) announced its 2021 preliminary annual results on Friday evening, reporting its loss narrowed 55.7% last year to 739 million yuan ($116 million),…
Recent Articles
Junshi hopes new scientist CEO can cure its woes
1877.HK
688180.SHG
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK
688150.SHG
RELATED ARTICLES
-
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
